Similarly, a meta-analysis by Tang et al. (2023) found that SGLT-2 inhibitors were associated with a significant reduction in the risk of both Alzheimer’s disease and vascular dementia [56]. This evidence concerns the gene SLC5A2 and early-onset autosomal dominant Alzheimer disease.